Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.47 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.